A real-world study of wearable sensors in Parkinson's disease
- PMID: 34845224
- PMCID: PMC8629990
- DOI: 10.1038/s41531-021-00248-w
A real-world study of wearable sensors in Parkinson's disease
Abstract
Most wearable sensor studies in Parkinson's disease have been conducted in the clinic and thus may not be a true representation of everyday symptoms and symptom variation. Our goal was to measure activity, gait, and tremor using wearable sensors inside and outside the clinic. In this observational study, we assessed motor features using wearable sensors developed by MC10, Inc. Participants wore five sensors, one on each limb and on the trunk, during an in-person clinic visit and for two days thereafter. Using the accelerometer data from the sensors, activity states (lying, sitting, standing, walking) were determined and steps per day were also computed by aggregating over 2 s walking intervals. For non-walking periods, tremor durations were identified that had a characteristic frequency between 3 and 10 Hz. We analyzed data from 17 individuals with Parkinson's disease and 17 age-matched controls over an average 45.4 h of sensor wear. Individuals with Parkinson's walked significantly less (median [inter-quartile range]: 4980 [2835-7163] steps/day) than controls (7367 [5106-8928] steps/day; P = 0.04). Tremor was present for 1.6 [0.4-5.9] hours (median [range]) per day in most-affected hands (MDS-UPDRS 3.17a or 3.17b = 1-4) of individuals with Parkinson's, which was significantly higher than the 0.5 [0.3-2.3] hours per day in less-affected hands (MDS-UPDRS 3.17a or 3.17b = 0). These results, which require replication in larger cohorts, advance our understanding of the manifestations of Parkinson's in real-world settings.
© 2021. The Author(s).
Conflict of interest statement
A commercial entity has engaged with the University of Rochester Technology Transfer Office to explore licensing of the analysis algorithms and code associated with this work for deployment on a cloud-based platform. Jamie L. Adams has no conflict of interest to report related to this paper. She received honoraria for speaking at the Huntington Study Group Annual Meeting; received compensation for consulting services from VisualDx; and research support from Azevan Pharmaceuticals, Biogen, Biohaven Pharmaceuticals, Biosensics, Empire Clinical Research Investigator Program, Michael J. Fox Foundation, National Institutes of Health/National Institute of Neurological Disorders and Stroke, NeuroNext Network, Pfizer, and Safra Foundation. Karthik Dinesh has no conflicts of interest related to this paper. He has received research support from MC10. Christopher W. Snyder, Mulin Xiong, and Saloni Sharma have no conflicts of interest to report related to the subject matter or materials discussed in the paper. Christopher G. Tarolli has no conflict of interest to report related to this paper. He has received honoraria for authorship for the American Academy of Neurology; and research support from the American Academy of Neurology Institute, Biosensics, Michael J. Fox Foundation, National Institutes of Health/National Institute of Neurological Disorders and Stroke, and Safra Foundation. E. Ray Dorsey has received honoraria for speaking at American Academy of Neurology courses, American Neurological Association, and University of Michigan; received compensation for consulting services from 23andMe, Abbott, Abbvie, American Well, Biogen, Clintrex, DeciBio, Denali Therapeutics, GlaxoSmithKline, Grand Rounds, Karger, Lundbeck, MC10, MedAvante, Medical-legal services, Mednick Associates, National Institute of Neurological Disorders and Stroke, Olson Research Group, Optio, Prilenia, Putnam Associates, Roche, Sanofi, Shire, Sunovion Pharma, Teva, UCB and Voyager Therapeutics; research support from Abbvie, Acadia Pharmaceuticals, AMC Health, Biosensics, Burroughs Wellcome Fund, Davis Phinney Foundation, Duke University, Food and Drug Administration, GlaxoSmithKline, Greater Rochester Health Foundation, Huntington Study Group, Michael J. Fox Foundation, National Institutes of Health/National Institute of Neurological Disorders and Stroke, National Science Foundation, Nuredis Pharmaceuticals, Patient-Centered Outcomes Research Institute, Pfizer, Prana Biotechnology, Raptor Pharmaceuticals, Roche, Safra Foundation, Teva Pharmaceuticals, University of California Irvine; editorial services for Karger Publications; and ownership interests with Blackfynn (data integration company) and Grand Rounds (second opinion service). Gaurav Sharma has no conflicts of interest related to this paper. He has received research support from MC10.
Figures
References
-
- Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson disease: a systematic review. Arch. Neurol. 2002;59:1724–1728. - PubMed
-
- Aarsland D, et al. The rate of cognitive decline in Parkinson disease. Arch. Neurol. 2004;61:1906–1911. - PubMed
-
- Gomez-Esteban JC, et al. Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson’s disease. J. Neurol. 2011;258:494–499. - PubMed
-
- Dorsey ER, Glidden AM, Holloway MR, Birbeck GL, Schwamm LH. Teleneurology and mobile technologies: the future of neurological care. Nat. Rev. Neurol. 2018;14:285–297. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
